GSK180（Cat No.:I006899）is a selective inhibitor of the metabolic enzyme glutaminase-1 (GLS1), developed by GlaxoSmithKline for cancer and metabolic disease research. GLS1 catalyzes the conversion of glutamine to glutamate, fueling the tricarboxylic acid (TCA) cycle and supporting tumor cell proliferation. By blocking glutamine metabolism, GSK180 disrupts cancer cell energy production and biosynthesis, making it a valuable tool for studying tumor metabolism. Preclinical studies demonstrated that GSK180 reduces growth in glutamine-dependent cancers, providing insights into therapeutic strategies targeting metabolic reprogramming in oncology.